P. Chrisp

发表

Nafarelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical potential in sex hormone-related conditions.

K. Goa, P. Chrisp, 1990, Drugs.

Co-Dergocrine Mesylate

A. N. Wadworth, P. Chrisp, 1992 .

Intranasal Salmon Calcitonin

A. Fitton, S. Clissold, P. Chrisp, 1991 .

Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical use in sex hormone-related conditions.

K. Goa, P. Chrisp, 1991, Drugs.

Levamisole/Fluorouracil

D. McTavish, P. Chrisp, 1991 .

Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease.

G. Mammen, E. Sorkin, P. Chrisp, 1991 .

Ocular Carteolol

E. Sorkin, P. Chrisp, 1992, Drugs & aging.

Flutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in advanced prostatic cancer.

R. N. Brogden, P. Chrisp, 1991, Drugs & aging.

Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis.

S. Clissold, P. Chrisp, 1991, Drugs.

Banbury Forum Consensus Statement on the Path Forward for Digital Mental Health Treatment.

D. Mohr, Tanzeem Choudhury, P. Areán, 2021, Psychiatric services.

- Drugs & Therapy Perspectives

K. Goa, G. Plosker, C. Spencer, 1996 .

Adenosine. An evaluation of its use in cardiac diagnostic procedures, and in the treatment of paroxysmal supraventricular tachycardia.

D. Faulds, M. M. Buckley, P. Chrisp, 1991, Drugs.

Moxonidine. A review of its pharmacology, and therapeutic use in essential hypertension.

D. Faulds, P. Chrisp, D Faulds, 1992, Drugs.

Reaching a shared understanding of shared decision making in health care: NICE's experience of scoping the shared decision making guideline.

N. Taske, P. Chrisp, K. Nolan, 2019, Journal of evaluation in clinical practice.

Nilutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer.

D. Faulds, P. Chrisp, S. G. Coleman, 1993, Drugs & aging.

Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy.

K. Goa, S. Ross, P. Chrisp, 1993, Drugs.

Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.

D. Faulds, J. Balfour, H. Langtry, 1991, Drugs.

Rimonabant: the evidence for its use in the treatment of obesity and the metabolic syndrome

P. Chrisp, Mark Waterlow, 2007, Core evidence.

Antifungal Antibiotics from Calcarisporium thermophilum: A New Source of 15-Azahomosterol Derivatives

P. Dewick, F. T. Boyle, P. Chrisp, 1990, Zeitschrift fur Naturforschung. C, Journal of biosciences.

Imipenem/Cilastatin

P. Benfield, P. Chrisp, 1992, PharmacoEconomics.

Place in therapy review Vildagliptin : the evidence for its place in the treatment of type 2 diabetes mellitus

P. Chrisp, L. Profit, Carole Nadin, 2009 .

Vildagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus

P. Chrisp, L. Profit, Carole Nadin, 2008, Core evidence.

Core evidence place in therapy summary for aprepitant in the prevention of chemotherapy-induced nausea and vomiting

P. Chrisp, 2009 .

Aprepitant: the evidence for its place in the prevention of chemotherapy-induced nausea and vomiting

P. Chrisp, 2007, Core evidence.

Fosaprepitant and aprepitant: an update of the evidence for their place in the prevention of chemotherapy-induced nausea and vomiting

Patrick Langford, P. Chrisp, Patrick Langford, 2010, Core evidence.

Leuprorelin. A review of its pharmacology and therapeutic use in prostatic disorders.

E. Sorkin, P. Chrisp, 1991, Drugs & aging.

Dilevalol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension.

K. Goa, P. Chrisp, 1990, Drugs.

Simvastatin

R. Milne, P. Chrisp, N. Lewis, 1992, PharmacoEconomics.

Ciclesonide in persistent asthma: the evidence of its therapeutic value

Charlotte A. Kenreigh, L. T. Wagner, P. Chrisp, 2006, Core evidence.

Lumiracoxib: the evidence of its clinical impact on the treatment of osteoarthritis

P. Chrisp, L. Profit, 2007, Core evidence.

Identifying a high-quality evidence base

Paul Chrisp, Sara Twaddle, S. Twaddle, 2014 .

Core evidence place in therapy summary for bevacizumab in NSCLC

P. Chrisp, S. Haslam, 2009 .

Bevacizumab: the evidence for its clinical potential in the treatment of nonsmall cell lung cancer

P. Chrisp, S. Haslam, 2007, Core evidence.

Place in therapy review Rimonabant : the evidence for its use in the treatment of obesity and the metabolic syndrome

P. Chrisp, Mark Waterlow, 2009 .

Selegiline: an appraisal of the basis of its pharmacoeconomic and quality-of-life benefits in Parkinson's disease.

R. Milne, H. Bryson, P. Chrisp, 1992, PharmacoEconomics.

Aripiprazole: the evidence of its therapeutic impact in schizophrenia

W. Winlow, P. Chrisp, L. Profit, 2006, Core evidence.

Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis.

S. Clissold, P. Chrisp, 1991, Drugs.

Biotechnology products

P. Chrisp, 1992 .

Co-dergocrine mesylate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in age-related cognitive decline.

A. N. Wadworth, P. Chrisp, 1992, Drugs & aging.

Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical use in sex hormone-related conditions.

K. Goa, P. Chrisp, 1991, Drugs.

Selegiline

G. Mammen, E. Sorkin, P. Chrisp, 1991 .

Flutamide

R. N. Brogden, P. Chrisp, 1991 .

Vildagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus

P. Chrisp, L. Profit, Carole Nadin, 2008, Core evidence.

Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.

D. Faulds, J. Balfour, P. Chrisp, 1991, Drugs.